Intellia Therapeutics, Inc. (NTLA)
Stock Price:
$24.59 USD
-1.18 (-4.58%)
Updated Oct 20, 2020 11:23 AM EDT - Market open
Key Info
| Market Cap |
1.44B |
| Revenue (ttm) |
50.73M |
| Net Income (ttm) |
-116.11M |
| Shares Out |
58.74M |
| EPS (ttm) |
-2.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$24.59 |
| Previous Close |
$25.77 |
| Change ($) |
-1.18 |
| Change (%) |
-4.58% |
| Day's Open |
25.73 |
| Day's Range |
24.27 - 26.35 |
| Day's Volume |
261,234 |
| 52-Week Range |
9.18 - 27.07 |
More Stats
| Market Cap |
1.44B |
| Enterprise Value |
1.03B |
| Earnings Date (est) |
Nov 3, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.74M |
| Float |
49.08M |
| EPS (basic) |
-2.31 |
| EPS (diluted) |
-2.30 |
| FCF / Share |
-0.78 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.94M |
| Short Ratio |
13.38 |
| Short % of Float |
24.32% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
28.47 |
| PB Ratio |
4.36 |
| Revenue |
50.73M |
| Operating Income |
-121.18M |
| Net Income |
-116.11M |
| Free Cash Flow |
-41.44M |
| Net Cash |
413.62M |
| Net Cash / Share |
7.04 |
| Gross Margin |
-128.74% |
| Operating Margin |
-238.87% |
| Profit Margin |
-228.90% |
| FCF Margin |
-81.68% |
| ROA |
-17.96% |
| ROE |
-36.95% |
| ROIC |
-53.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (13)
| Buy |
7 |
| Overweight |
2 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.55*
(20.17% upside)
Low
20.0
Current: $24.59
High
46.0
Target: 29.55
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 43.10 | 30.43 | 26.12 | 16.48 | 6.04 |
| Revenue Growth | 41.63% | 16.53% | 58.49% | 172.65% | - |
| Gross Profit | 43.10 | 30.43 | 26.12 | 16.48 | 6.04 |
| Operating Income | -106 | -90.87 | -69.56 | -32.16 | -13.41 |
| Net Income | -99.53 | -85.34 | -67.54 | -31.63 | -12.40 |
| Shares Outstanding | 47.25 | 43.07 | 36.01 | 22.22 | 0.24 |
| Earnings Per Share | -2.11 | -1.98 | -1.88 | -1.42 | -51.02 |
| Operating Cash Flow | -103 | -61.26 | -65.28 | 36.11 | -1.76 |
| Capital Expenditures | -6.79 | -6.23 | -10.09 | -6.17 | -2.55 |
| Free Cash Flow | -110 | -67.48 | -75.37 | 29.94 | -4.32 |
| Cash & Equivalents | 280 | 314 | 341 | 273 | 75.82 |
| Total Debt | 18.38 | - | - | - | - |
| Net Cash / Debt | 261 | 314 | 341 | 273 | 75.82 |
| Assets | 334 | 347 | 376 | 299 | 82.14 |
| Liabilities | 64.40 | 69.40 | 75.64 | 89.13 | 103 |
| Book Value | 270 | 278 | 301 | 210 | -21.20 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Intellia Therapeutics, Inc. |
| Country |
United States |
| Employees |
270 |
| CEO |
John M. Leonard |
Stock Information
| Ticker Symbol |
NTLA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NTLA |
| IPO Date |
May 6, 2016 |
Description
Intellia Therapeutics, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.